For breast cancer cells, IL-6/JAK/Stat3 signaling pathway is essential to maintain the CSCs property (CD44+CD24− cells), which suggested a prospective therapy mean to target the stem-like breast cancer cells [35]. This evidence concerns the gene IL6 and breast carcinoma.